Safety and Efficacy of CKDB-501B in Subjects With Moderate-to-severe Glabellar Lines
NCT05428930
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Glabellar Lines
Interventions
DRUG:
CKDB-501B
DRUG:
Botox®50U
Sponsor
CKD Bio Corporation